U.S. pharma giant copyright scrapped two experimental weight loss capsules previous calendar year—a once-day-to-day capsule, lotiglipron, as a consequence of elevated liver enzymes and a 2 times-every day pill, danuglipron, as a result of solid Negative effects—but CEO Albert Bourla has explained the company is set to “Perform and acquire”